Ann: Phosphagenics Arbitration Award Issued, page-175

From the Announcement can somebody please tell what this actually means in terms going forward.

“
The company says the licensing agreement remains in place, requiring Mylan to continue to take “commercially reasonable efforts to develop TPM-daptomycin, not to sell a generic daptomycin and to pay royalties to Phosphagencis on commercial sales.

“Phosphagenics may be required to enforce its remaining rights to require Mylan to act in line with requirements of the licencing agreement,” the company says.